ArticleInternational ophthalmology2012
The mystery of angiographically silent macular oedema due to taxanes.
Article in International ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis.Breast cancer research and treatment · 2025Article
- Efficacy of topical carbonic anhydrase inhibitors in treating taxane drug-induced cystoid macular edema: A case report.Medicine · 2025Article
- Article
- Retinal phototoxicity after macular hole surgery in a patient under paclitaxel.BMC ophthalmology · 2023Article
- Cystoid macular oedema without leakage in fluorescein angiography: a literature review.Eye (London, England) · 2023Review
- Taxane-Induced Neuropathy and Its Ocular Effects-A Longitudinal Follow-up Study in Breast Cancer Patients.Cancers · 2023Article
- Bilateral intermediate uveitis following treatment with paclitaxel in a patient with invasive ductal carcinoma of the breast.International journal of retina and vitreous · 2022Article
- Paclitaxel may be a risk factor for retinal phototoxicity.American journal of ophthalmology case reports · 2022Article
- The effect of docetaxel on retinal pigment epithelial cells.Toxicology reports · 2022Article
- Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports.Journal of medical case reports · 2021Article
- Optical coherence tomography characteristics of taxane-induced macular edema and other multimodal imaging findings.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Article
- Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy.American journal of ophthalmology case reports · 2020Article
- Docetaxel-induced maculopathy possibly potentiated by concurrent hydroxychloroquine use.American journal of ophthalmology case reports · 2019Article
- Impaired retinal pigment epithelium in paclitaxel-induced macular edema: A case report.Medicine · 2018Article
- Indocyanine green angiography findings of cystoid macular edema secondary to paclitaxel therapy.Japanese journal of ophthalmology · 2018Article
- Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema.BMJ case reports · 2016Article
- Bilateral cystoid macular edema following docetaxel chemotherapy in a patient with retinitis pigmentosa: a case report.BMC ophthalmology · 2015Article
- Sub-Tenon Injections of Triamcinolone Acetonide Had Limited Effect on Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound-Paclitaxel (Abraxane).Case reports in ophthalmological medicine · 2015Article
- Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review.OncoTargets and therapy · 2014Article
- Drug-induced macular edema.Drugs · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Taxanes are widely used anticancer agents, produced from the plants of the genus Taxus (yews). One of the rare side-effects caused by taxanes is a bilateral cystoid macular oedema (CMO). The particularity of this type of CMO is that it is angiographically silent showing no leakage or pooling on fluorescein angiography (FA). To date, the mechanism of this oedema has not been clearly understood and existing theories do not explain this phenomenon very well. Our aim was to report a case of paclitaxel-induced CMO and put forward a putative explanation for this occurrence. A 64-year-old woman presented with a 7-month history of progressively decreasing bilateral visual acuity with an apparently normal fundus. At entry her best-corrected visual acuity (BCVA) was 0.4 for far and near OD and 0.5 for far and near OS. Optical coherence tomography (OCT) revealed a CMO with a central thickness of 561 μm OD and 488 μm OS; there were no signs of intraocular inflammation. FA showed no capillary leakage and quasi absent late hyperfluorescence OU. Indocyanine green angiography was within normal limits. Classical CMO treatment was ineffective and only discontinuation of paclitaxel resulted in recovery of a normal macular structure after 4 weeks with an increase of BCVA to 0.9 OD and 1.0 OS. In order to understand the properties of taxane drug-induced cystoid macular oedema (TDICMO) we compared the spectral OCT findings of our case to an inflammation-induced CMO of equal thickness and to a case of multifocal choroiditis. The plane of separation of TDICMO was above the external limiting membrane in both cases. In contrast to inflammation-induced CMO where the four external bands were well identified, there was attenuation of these bands in TDICMO but no disruption of the layers as seen in multifocal choroiditis, indicating that the fluid in TDICMO had a high viscosity producing a shadow underneath. TDICMO most probably originates from retinal pigment epithelium dysfunction by their effect on microtubule functions and not from vascular leakage. The content of the CMO seems to be made up of viscous fluid. As the origin of the CMO is not inflammatory, classical CMO treatments have no effect and only discontinuation of the taxane drug allows reversal of the CMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.